TY - JOUR
T1 - Are androgen receptor variants a substitute for the full-length receptor?
AU - Lu, Ji
AU - Der Steen, Travis Van
AU - Tindall, Donald J.
PY - 2015/3/11
Y1 - 2015/3/11
N2 - Androgen receptor splice variants (AR-Vs) - which are expressed in castration-resistant prostate cancer (CRPC) cell lines and clinical samples - lack the C-terminal ligand-binding domain and are constitutively active. AR-Vs are, therefore, resistant to traditional androgen deprivation therapy (ADT). AR-Vs are induced by several mechanisms, including ADT, and might contribute to the progression of CRPC and resistance to ADT. AR-Vs could represent a novel therapeutic target for prostate cancer, especially in CRPC.
AB - Androgen receptor splice variants (AR-Vs) - which are expressed in castration-resistant prostate cancer (CRPC) cell lines and clinical samples - lack the C-terminal ligand-binding domain and are constitutively active. AR-Vs are, therefore, resistant to traditional androgen deprivation therapy (ADT). AR-Vs are induced by several mechanisms, including ADT, and might contribute to the progression of CRPC and resistance to ADT. AR-Vs could represent a novel therapeutic target for prostate cancer, especially in CRPC.
UR - http://www.scopus.com/inward/record.url?scp=84924533221&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924533221&partnerID=8YFLogxK
U2 - 10.1038/nrurol.2015.13
DO - 10.1038/nrurol.2015.13
M3 - Review article
C2 - 25666893
AN - SCOPUS:84924533221
SN - 1759-4812
VL - 12
SP - 137
EP - 144
JO - Nature Reviews Urology
JF - Nature Reviews Urology
IS - 3
ER -